Preliminary Investigation of the Antibacterial Activity of Antitumor Drug 3-Amino-1,2,4-Benzotriazine-1,4-Dioxide (Tirapazamine) and its Derivatives
Open Access
- 12 June 2020
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 10 (12) , 4062
Abstract
The antitumor drug 3-amino-1,2,4-benzotriazine-1,4-dioxide (tirapazamine, TPZ (1)) along with a number of newly synthesized tirapazamine derivatives (TPZs) bearing substitutions at the 3-amine position of TPZ (1) were estimated for their antibacterial activity against representative Gram-negative Escherichia coli (ATCC 25922) and Salmonella enterica (SL 5676), as well as Gram-positive Staphylococcus aureus (ATCC 25923) bacterial strains. Their activities in terms of minimum inhibitory concentrations (MICs) varied in the range of 1.1 µM (0.25 µg/mL)–413 µM (128 µg/mL). Amongst the most potent derivatives (1–6), acetyl- and methoxycarbonyl-substituted TPZs (2 and 4) were the strongest agents, which exhibited approximately 4–30 fold greater activities compared to those of TPZ (1) along with the reference drugs chloramphenicol (CAM) and nitrofurantoin (NFT). The inhibitory activities of the compounds were highly impacted by their structural features. No reliable relationships were established between activities and the electron-accepting potencies of the whole set of studied compounds, while the activities of TPZ drug (1) and the structurally uniform set of molecules (2–6) were found to increase with an increase in their electron-accepting potencies obtained by means of density functional theory (DFT) computation. A greater steric, lipophilic and polar nature of the substituents led to a lower activity of the compounds. The combined antibacterial in vitro trial gave clear evidence that TPZs coupled with the commonly utilized antibiotics ciprofloxacin (Cipro) and nitrofurantoin (NFT) could generate enhanced (suggestive of partial and virtually complete synergistic) and additive effects. The strongest effects were defined for TPZs–NFT combinations, which resulted in a notable reduction in the MICs of di-N-oxides. These preliminary findings suggest that the synthesized novel di-N-oxides might be used as sole agents or applied as antibiotic complements.Keywords
This publication has 53 references indexed in Scilit:
- The anticancer drug tirapazamine has antimicrobial activity againstEscherichia coli,Staphylococcus aureusandClostridium difficileFEMS Microbiology Letters, 2013
- Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives as Hypoxic Selective Anti-tumor AgentsMolecules, 2012
- Combination Therapy for Treatment of Infections with Gram-Negative BacteriaClinical Microbiology Reviews, 2012
- Studies on Log Po/w of Quinoxaline di-N-Oxides: A Comparison of RP-HPLC Experimental and Predictive ApproachesMolecules, 2011
- Contribution of Target Gene Mutations and Efflux to Decreased Susceptibility of Salmonella enterica Serovar Typhimurium to Fluoroquinolones and Other AntimicrobialsAntimicrobial Agents and Chemotherapy, 2007
- Involvement of Reactive Oxygen Species in the Action of Ciprofloxacin againstEscherichia coliAntimicrobial Agents and Chemotherapy, 2006
- QUORUM SENSING: Cell-to-Cell Communication in BacteriaAnnual Review of Cell and Developmental Biology, 2005
- Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxiaExpert Opinion on Investigational Drugs, 2000
- Empirical methods for computing molecular partition coefficients: II. Inclusion of conformational flexibility within fragment–based approachesInternational Journal of Quantum Chemistry, 1992
- Cyclic voltammetry of phenazines and quinoxalines including mono- and di-N-oxides. Relation to structure and antimicrobial activityChemico-Biological Interactions, 1986